ABSTRACT
This chapter presents a concise characterization of neurological diseases such as Alzheimer’s disease (AD), Parkinson’s disease, Huntington’s disease, multiple sclerosis, amyotrophic lateral sclerosis, Friedrich ataxia, ischemic stroke, and epilepsy with trademark indicators extensively used in the metallic nanoparticles (MNPs) field, a summary of advanced and powerful MNPs used for therapeutics and detection, as well as encouraging initiatives to enhance blood-brain barrier infiltration and/or disease approaching the efficiency of MNPs. Some medically authorized medications could only relieve signs or slow the development of AD by procuring neurotransmitters that also enhance interconnections among nerve cells in Alzheimer’s patients’ brains. The use of nanotechnology in tissue regeneration is estimated to increase the recuperative and pharmacological benefits of stem cell transplants as well as the identification of AD. The use of platinum nanoparticles improved motor activities and lessened brain infarct amplitude substantially. Anti-epileptic drugs and surgery are used to cure epilepsy when drug resistance develops as a consequence of prolonged chemoradiation therapy.
